---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010747"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:37:00.890310+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025

## Summary
- CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.
- J-code effective April 1, 2025, streamlines billing and reimbursement for providers.
- LYMPHIR approved by FDA for relapsed/refractory Stage I-III CTCL after prior systemic therapy.
- CEO Leonard Mazur says J-code is critical for patient access and coverage by commercial & government insurers.

## SEC filing metadata
- accession: 0001213900-25-010747
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/0001213900-25-010747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/ea0230159-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010747
- JSON: https://secwatch.observer/filing/0001213900-25-010747.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.